ResearcherArmy Medical UniversityNo recent work listed
Da Li
Matched on ORCID iD 0000-0003-2923-8752; OpenAlex author ID A5100384554. Sources: OpenAlex.
Their work
- Papers
- 4 (first author 0, last author 3)
- Trials
- 0
- Grants
- 0
- Labs led
- 1
- Collaborators
- 31
2018: 2 papers · 2019: none · 2020: none · 2021: none · 2022: 2 papers
Papers 4
- Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of pancreatic cancer. Co-author DOI 10.1016/j.jncc.2022.08.006↗
- Corrigendum to "Suppression of IL-6 Gene by shRNA Augments Gemcitabine Chemosensitization in Pancreatic Adenocarcinoma Cells". Last author DOI 10.1155/2022/9767389↗
- Suppression of IL-6 Gene by shRNA Augments Gemcitabine Chemosensitization in Pancreatic Adenocarcinoma Cells. Last author DOI 10.1155/2018/3195025↗
- Diagnostic Value of CA 19-9 and Carcinoembryonic Antigen for Pancreatic Cancer: A Meta-Analysis. Last author DOI 10.1155/2018/8704751↗
Closest collaborators
The 25 strongest of 31 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Haibo Xing · 3 shared papers, 2018–2022 · strength 0.36
- Paper Corrigendum to "Suppression of IL-6 Gene by shRNA Augments Gemcitabine Chemosensitization in Pancreatic Adenocarcinoma … DOI 10.1155/2022/9767389↗
- Paper Suppression of IL-6 Gene by shRNA Augments Gemcitabine Chemosensitization in Pancreatic Adenocarcinoma Cells. DOI 10.1155/2018/3195025↗
- Paper Diagnostic Value of CA 19-9 and Carcinoembryonic Antigen for Pancreatic Cancer: A Meta-Analysis. DOI 10.1155/2018/8704751↗
- Mengting Tong · 3 shared papers, 2018–2022 · strength 0.36
- Paper Corrigendum to "Suppression of IL-6 Gene by shRNA Augments Gemcitabine Chemosensitization in Pancreatic Adenocarcinoma … DOI 10.1155/2022/9767389↗
- Paper Suppression of IL-6 Gene by shRNA Augments Gemcitabine Chemosensitization in Pancreatic Adenocarcinoma Cells. DOI 10.1155/2018/3195025↗
- Paper Diagnostic Value of CA 19-9 and Carcinoembryonic Antigen for Pancreatic Cancer: A Meta-Analysis. DOI 10.1155/2018/8704751↗
- Feng Jiao · 1 shared paper, 2022 · strength 0.09
- Zheng Wang · 1 shared paper, 2022 · strength 0.09
- Zhiwei Li · 1 shared paper, 2022 · strength 0.09
- Tao Zhang · 1 shared paper, 2022 · strength 0.09
- Qingyong Ma · 1 shared paper, 2022 · strength 0.09
- Liwei Wang · 1 shared paper, 2022 · strength 0.09
- Chunyi Hao · 1 shared paper, 2022 · strength 0.09
- Gang Ren · 1 shared paper, 2022 · strength 0.09
- Jie Chen · 1 shared paper, 2022 · strength 0.09
- Dan Cao · 1 shared paper, 2022 · strength 0.09
- Jian Wang · 1 shared paper, 2022 · strength 0.09
- Yongrui Bai · 1 shared paper, 2022 · strength 0.09
- Zhihong Zhang · 1 shared paper, 2022 · strength 0.09
- Yongwei Sun · 1 shared paper, 2022 · strength 0.09
- Ji Li · 1 shared paper, 2022 · strength 0.09
- Jianping Xiong · 1 shared paper, 2022 · strength 0.09
- Jun Zhou · 1 shared paper, 2022 · strength 0.09
- Feng‐Hua Wang · 1 shared paper, 2022 · strength 0.09
- Leizhen Zheng · 1 shared paper, 2022 · strength 0.09
- Chengfeng Wang · 1 shared paper, 2022 · strength 0.09
- Xianbao Zhan · 1 shared paper, 2022 · strength 0.09
- Enxiao Li · 1 shared paper, 2022 · strength 0.09
- Jihui Hao · 1 shared paper, 2022 · strength 0.09
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.